Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial.
Hermann R, Grobost V, Le-Guillou X, Lavigne C, Parrot A, Rivière S, Séguier J, Fargeton AE, de-Montigny A, Huot M, Decullier E, Roux A, Gervaise C, Cartier C, Dufour X, Grall M, Jegoux F, Laccourreye L, Michel J, Saroul N, Wagner I, Kerjouan M, Dupuis-Girod S. Hermann R, et al. Among authors: dupuis girod s. Angiogenesis. 2024 Dec 24;28(1):9. doi: 10.1007/s10456-024-09962-4. Angiogenesis. 2024. PMID: 39718659 Free PMC article. Clinical Trial.
ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F. Dupuis-Girod S, et al. MAbs. 2014 May-Jun;6(3):794-9. doi: 10.4161/mabs.28025. Epub 2014 Jan 30. MAbs. 2014. PMID: 24481211 Free PMC article. Clinical Trial.
Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Bréant V, Colombet B, Rivière S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F. Dupuis-Girod S, et al. JAMA. 2016 Sep 6;316(9):934-42. doi: 10.1001/jama.2016.11387. JAMA. 2016. PMID: 27599328 Clinical Trial.
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
Dupuis-Girod S, Fargeton AE, Grobost V, Rivière S, Beaudoin M, Decullier E, Bernard L, Bréant V, Colombet B, Philouze P, Bailly S, Faure F, Hermann R. Dupuis-Girod S, et al. J Clin Med. 2020 Apr 26;9(5):1262. doi: 10.3390/jcm9051262. J Clin Med. 2020. PMID: 32357559 Free PMC article.
Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL).
Grobost V, Hammi S, Pereira B, Guilhem A, Duffau P, Seguier J, Parrot A, Gautier G, Alric L, Kerjouan M, Le Guillou X, Simon D, Chaussavoine L, Rondeau-Lutz M, Leguy-Seguin V, Delagrange L, Lavigne C, Maillard H, Dupuis-Girod S; French HHT group. Grobost V, et al. Thromb Res. 2023 Sep;229:107-113. doi: 10.1016/j.thromres.2023.07.001. Epub 2023 Jul 6. Thromb Res. 2023. PMID: 37437516
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T. Dupuis-Girod S, et al. J Intern Med. 2023 Dec;294(6):761-774. doi: 10.1111/joim.13714. Epub 2023 Aug 23. J Intern Med. 2023. PMID: 37592715 Clinical Trial.
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Dupuis-Girod S, et al. JAMA. 2012 Mar 7;307(9):948-55. doi: 10.1001/jama.2012.250. JAMA. 2012. PMID: 22396517 Clinical Trial.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. Azzopardi N, et al. MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693. MAbs. 2015. PMID: 25751241 Free PMC article.
126 results